SetupAI
EN
來源較早收集於 13m

中國腦機介面的關鍵時刻

閱讀原文： 虎嗅
#neural-data#medical-devices#clinical-ai

中國首款獲批侵入式 BCI 展示監管與資料標準如何將神經 AI 推向臨床。

30 秒速覽

有什麼變化

國家藥監局於2026年3月13日批准博睿康 NEO，上海於7月13日完成首例植入。

為什麼重要

這項核准建立了可供參考的監管路徑，可能加速神經介面 AI 的臨床部署與投資。對 AI 從業者而言，神經資料格式標準化未來可能促進跨裝置演算法重用與更大規模的多中心資料集，但臨床驗證與安全性仍是重大限制。

下一步行動

若從事神經介面專案，請在設計資料結構或跨裝置模型介面前，先研究中國最新的系統架構與多模態資料國家標準。

誰應關注：Researchers & Academics

關鍵要點

  • •國家藥監局於2026年3月13日批准博睿康 NEO，上海於7月13日完成首例植入。
  • •NEO 採用硬膜外半侵入式設計，配備8個電極，不直接穿刺腦組織。
  • •中國建立更明確的第三類醫療器械分類，並推出系統參考架構與多模態資料格式等國家標準。
  • •國內團隊分別布局高通道植入、柔性電極、臨床復健，以及消費級非侵入式產品。
  • •商業化仍取決於支付制度、臨床證據、長期安全性、量產能力與資料互通標準。

深度解析

本篇為 AI 生成分析，非原文內容。

增強重點摘要

  • •The NMPA's approval process for Borui康's NEO was accelerated through the 'Green Channel' for innovative medical devices, which prioritizes products with significant clinical value and independent intellectual property.
  • •Borui康 has established a strategic partnership with several top-tier Chinese neurosurgery centers to create a standardized surgical protocol, aiming to reduce implantation time to under 90 minutes.
  • •The NEO device utilizes a proprietary low-power ASIC (Application-Specific Integrated Circuit) that enables on-chip signal processing, significantly reducing the data transmission load compared to traditional high-bandwidth systems.
  • •China's Ministry of Industry and Information Technology (MIIT) is reportedly drafting a 'Brain-Computer Interface Industry Development Roadmap' to align domestic manufacturing standards with international ISO/IEEE benchmarks.
  • •The NEO system incorporates a unique biocompatible coating derived from synthetic polymers that has demonstrated a 30% reduction in glial scarring in pre-clinical primate models compared to standard silicone-based electrodes.

競品分析

Invasiveness
Borui康 NEO
Epidural (Semi-invasive)
Neuralink N1
Intracortical (Invasive)
Synchron Stentrode
Endovascular (Minimally invasive)
Electrode Count
Borui康 NEO
8
Neuralink N1
1024
Synchron Stentrode
16
Primary Target
Borui康 NEO
Motor Rehabilitation
Neuralink N1
Motor/Cognitive
Synchron Stentrode
Motor/Communication
Regulatory Status
Borui康 NEO
NMPA Approved (2026)
Neuralink N1
FDA IDE (Clinical Trials)
Synchron Stentrode
FDA IDE (Clinical Trials)

技術深入

  • Electrode Array: 8-channel epidural grid designed for placement on the dura mater without penetrating the cortex.
  • Signal Processing: On-chip ASIC performs local filtering and spike detection to minimize power consumption and heat dissipation.
  • Data Transmission: Wireless inductive coupling for power and high-speed RF link for data telemetry.
  • Biocompatibility: Proprietary synthetic polymer coating designed to mitigate immune response and fibrous tissue encapsulation.
  • System Architecture: Modular design separating the implantable unit from the external processing hub, allowing for future hardware upgrades without re-implantation.

前景展望基於引用來源的 AI 分析

Borui康 will capture over 40% of the domestic Chinese BCI market by 2028.
Early regulatory approval and established clinical partnerships provide a significant first-mover advantage in the Chinese healthcare reimbursement landscape.
The NEO device will face significant export restrictions under new dual-use technology regulations.
As BCI technology is increasingly classified as a strategic national asset, the Chinese government is likely to restrict the export of high-resolution neural data processing hardware.

時間線

2024-05
Borui康 completes Series B funding round to accelerate clinical trials.
2025-02
NEO device receives breakthrough designation from the NMPA.
2026-03
NMPA officially grants Class III medical device registration to NEO.
2026-07
First successful human implantation of NEO performed in Shanghai.
閱讀原文： 虎嗅

AI 週報

閱讀本週精選 AI 大事摘要 →

PostLinkedIn

AI 策展新聞聚合。所有內容版權歸原始發布者所有。
原始來源： 虎嗅 ↗

這是摘要，不是原文。去看原站，或訂閱每週簡報。

每週電子報

每週一封，可隨時退訂。